JP2013538853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538853A5 JP2013538853A5 JP2013531717A JP2013531717A JP2013538853A5 JP 2013538853 A5 JP2013538853 A5 JP 2013538853A5 JP 2013531717 A JP2013531717 A JP 2013531717A JP 2013531717 A JP2013531717 A JP 2013531717A JP 2013538853 A5 JP2013538853 A5 JP 2013538853A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- topical pharmaceutical
- oxymetazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 11
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 6
- 229960003679 brimonidine Drugs 0.000 claims 6
- 229960001528 oxymetazoline Drugs 0.000 claims 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38726010P | 2010-09-28 | 2010-09-28 | |
| US61/387,260 | 2010-09-28 | ||
| US13/232,134 | 2011-09-14 | ||
| US13/232,134 US20120082625A1 (en) | 2010-09-28 | 2011-09-14 | Combination treatment for rosacea |
| PCT/US2011/053440 WO2012047645A2 (en) | 2010-09-28 | 2011-09-27 | Combination treatment for rosacea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538853A JP2013538853A (ja) | 2013-10-17 |
| JP2013538853A5 true JP2013538853A5 (enExample) | 2014-09-18 |
Family
ID=45890007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531717A Pending JP2013538853A (ja) | 2010-09-28 | 2011-09-27 | 酒瘡の併用による治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20120082625A1 (enExample) |
| EP (1) | EP2621497A4 (enExample) |
| JP (1) | JP2013538853A (enExample) |
| KR (1) | KR20140056130A (enExample) |
| CN (1) | CN103354743A (enExample) |
| AU (1) | AU2011312518A1 (enExample) |
| BR (1) | BR112013007343A2 (enExample) |
| CA (1) | CA2811783A1 (enExample) |
| MX (1) | MX2013003638A (enExample) |
| RU (1) | RU2013113184A (enExample) |
| WO (1) | WO2012047645A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| EP3181121B1 (en) | 2010-12-03 | 2020-10-28 | EPI Health, LLC | Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea |
| BR112013020770A2 (pt) | 2011-02-15 | 2019-08-27 | Allergan Inc | composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea |
| CN104666239A (zh) * | 2013-11-27 | 2015-06-03 | 杭州赛利药物研究所有限公司 | 酒石酸溴莫尼定凝胶及其制备方法 |
| JP2018506570A (ja) * | 2015-02-24 | 2018-03-08 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | ドライアイ疾患及び他の眼障害の治療のための方法及び組成物 |
| US9989950B2 (en) | 2015-07-17 | 2018-06-05 | General Electric Company | Systems and methods for generating control logic |
| FR3041537B1 (fr) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee. |
| EP3434271B1 (en) * | 2016-03-22 | 2020-08-26 | Doris Maria Hexsel | Use of pharmaceutical composition for the treatment of poikiloderma of civatte |
| WO2018000067A1 (pt) * | 2016-06-28 | 2018-01-04 | Doris Maria Hexsel | Uso de uma substância ativa no tratamento do melasma telangiectásico |
| KR20190071720A (ko) | 2016-10-07 | 2019-06-24 | 마이크레오스 휴먼 헬스 비.브이. | 주사의 혈관수축성 및 항균성 병용 치료 |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| RU2766973C1 (ru) * | 2021-10-05 | 2022-03-16 | Татьяна Сергеевна Русина | Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| CN104490884A (zh) * | 2004-05-25 | 2015-04-08 | 桑斯罗萨医药发展公司 | 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 |
| EP2818184B1 (en) * | 2007-11-16 | 2018-10-31 | Allergan, Inc. | Compositions and methods for treating Purpura |
| FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
-
2011
- 2011-09-14 US US13/232,134 patent/US20120082625A1/en not_active Abandoned
- 2011-09-27 RU RU2013113184/15A patent/RU2013113184A/ru not_active Application Discontinuation
- 2011-09-27 JP JP2013531717A patent/JP2013538853A/ja active Pending
- 2011-09-27 KR KR1020137010904A patent/KR20140056130A/ko not_active Ceased
- 2011-09-27 AU AU2011312518A patent/AU2011312518A1/en not_active Abandoned
- 2011-09-27 CA CA2811783A patent/CA2811783A1/en not_active Abandoned
- 2011-09-27 CN CN2011800470779A patent/CN103354743A/zh active Pending
- 2011-09-27 EP EP11831290.9A patent/EP2621497A4/en not_active Withdrawn
- 2011-09-27 BR BR112013007343A patent/BR112013007343A2/pt not_active IP Right Cessation
- 2011-09-27 MX MX2013003638A patent/MX2013003638A/es unknown
- 2011-09-27 WO PCT/US2011/053440 patent/WO2012047645A2/en not_active Ceased
-
2013
- 2013-12-09 US US14/100,450 patent/US20140100232A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,519 patent/US20150313894A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538853A5 (enExample) | ||
| RU2013113184A (ru) | Комбинированное лечение розацеа | |
| JP2013542930A5 (enExample) | ||
| WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| WO2012160180A3 (en) | Pharmaceutical composition for administration to nails | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| CL2014003081A1 (es) | Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis. | |
| CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
| NZ600333A (en) | Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis | |
| JP2013511534A5 (enExample) | ||
| HUE061596T2 (hu) | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben | |
| JP2017537936A5 (enExample) | ||
| MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
| JP2016512246A5 (enExample) | ||
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| CO6592109A2 (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida | |
| FR2997299B1 (fr) | Association d'extraits de plantes, ingredient actif cosmetique et composition les contenant, et utilisation topique cosmetique | |
| DK2802319T3 (da) | Fastdosiskombinationsterapi for parkinsons sygdom | |
| WO2013092457A3 (de) | Wirkstoffkombinationen aus einer oder mehreren carbonsäuren, insbesondere hydroxycarbonsäuren, und einer oder mehreren physiologisch unbedenklichen hydroxamsäure sowie kosmetische oder dermatologische zubereitungen, solche wirkstoffkombinationen enthaltend | |
| WO2013182998A4 (en) | Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes | |
| HRP20161135T1 (hr) | Oblici u krutom stanju n-((s)-2,3-dihidroksi-propil)-3-(2-fluoro-4-jodo-fenilamino)-izonikotinamida | |
| JP2014530847A5 (enExample) |